As part of the Severo Ochoa Patient and Citizen Involvement Programme, the 4th Patient Day was held on 10 April,…
featured news home
Results of a VHIO led study show that up to 90% of chronically hypoxic patients have an EPAS1 alteration in…
Led by investigators of VHIO’s Radiomics Group, a review article published in ESMO Real-World Data and Digital Oncology—the European Society…
Co-authored by leading experts in oncology, a review article recently published in the Journal of Clinical Oncology (JCO)* provides an…
The American Association for Cancer Research (AACR) has officially announced this year’s class of Fellows of the AACR Academy. The…
Initial results of the COMPETE phase 3 clinical trial—the first study to compare targeted radioligand therapy with molecular targeted therapy…
The MYC oncogene is deregulated in approximately 70% of human cancers and is associated with aggressive disease and cancer drug resistance,…
Results of the multi-center, international phase 3 TALAPRO-2 trial show that the combination of PARP inhibitor talazoparib plus anti-androgen enzalutamide…
The second Joint Action of the EU on Networks of Expertise on Cancer (JANE-2) officially launched on January 28-29, 2025,…
The Paseíco de la Mama solidarity initiative has enabled VHIO’s Breast Cancer Group to carry out numerous research projects over…
